

Message

From: Michael Dourson [dourson@tera.org]
Sent: 3/4/2021 8:04:33 PM
To: akihi koh@dranihs.net; Janet Anderson [jkanderson@gsi-net.com]; Joseph Annotti [jannotti@truthinscience.org]; Behl, Betsy [Behl.Betsy@epa.gov]; Bertrand, Charlotte [Bertrand.Charlotte@epa.gov]; Boobis, Alan R [a.boobis@imperial.ac.uk]; [Ex. 6 Personal Privacy (PP)] oss.a.brittain@wv.gov; Edward Calabrese [edwardc@schoolph.umass.edu]; jill.clark@dnr.ga.gov; Harvey Clewell [hclewell@ramboll.com]; Joseph Cotruvo (Aol) [Ex. 6 Personal Privacy (PP)]; Cox, Kevin [kcox@nsf.org]; Davis, Kevin [kdavis2@idem.in.gov]; Deshpande, Satish (MECP) [Satish.Deshpande@ontario.ca]; beth.dittman@dhhs.nc.gov; Mike Easter [measter@ensight.net]; [Ex. 6 Personal Privacy (PP)] Suzanne_Fitzpatrick [Suzanne.Fitzpatrick@fda.hhs.gov]; flagac@michigan.gov; Gillay, David [David.Gillay@btlaw.com]; gary.ginsberg@health.ny.gov; Giffe Johnson [gjohanson@ncasi.org]; Jonathan Gledhill [jgledhill@policynavigation.com]; Þórhallur Ingi Halldórsson [tih@hi.is]; Holm, Stewart [Stewart_Holm@afandpa.org]; Joseph.Haney@tceq.texas.gov; A. Wallace Haye [Ex. 6 Personal Privacy (PP)] [Ex. 6 Personal Privacy (PP)] elen.goeden@state.mn.us; Andrea Hinwood [andrea.hinwood@epa.vic.gov.au]; Michael Honeycutt [Michael.honeycutt@tceq.texas.gov]; Mark S. Johnson [Ex. 6 Personal Privacy (PP)] Steve Koenigsberg [skoenigsberg@enrxinc.com]; Krapfl, Heidi, DOH [Heidi.Krapfl@state.nm.us]; sabine.lange@tceq.texas.gov; Ratin Mathur [Ratin.Mathur@crccare.com]; mariko@nihs.go.jp; Ravi Naidu (CRCCARE) [Ravi.Naidu@crccare.com]; Orme-Zavaleta, Jennifer [Orme-Zavaleta.Jennifer@epa.gov]; Greg Paoli [gpaoli@risksciences.com]; Gloria.Post@dep.nj.gov; amy.potter@dnr.ga.gov [Amy.Potter@dnr.ga.gov]; prui@cdc.gov; Tucker, Brian [Brian.Tucker@epa.ohio.gov]; cer2 [cer2@cdc.gov]; rieds@michigan.gov; Risotto, Steve [Steve_Risotto@americanchemistry.com]; Robert Scal [Ex. 6 Personal Privacy (PP)] rroy@mmm.com; Schlosser, Paul [Schlosser.Paul@epa.gov]; John Simon [jsimon@nathaninc.com]; [Ex. 6 Personal Privacy (PP)] roberts, Stephen M [smroberts@ufl.edu]; Thayer, Kris [thayer.kris@epa.gov]; svia@awwa.org; [Ex. 6 Personal Privacy (PP)] nil; Walles, Todd K. [Todd.Walles@WestonSolutions.com]; Rick Welsh [rwelsh@asti-env.com]; wildfange@michigan.gov
CC: Bernard Gadagbui [gadagbui@tera.org]
Subject: Re: Alliance for Risk Assessment: Workshop XII of Beyond Science and Decisions: Preliminary Research Case Study on PFOA 1/2 life
Attachments: PastedGraphic-1.pdf; Email Correspondence after the Beyond Science and Decisions Workshop XII regarding the case study on PFOA.docx

Dear Colleagues

The preliminary research case study on PFOA 1/2 life got excellent feedback at last week's workshop, not the least of which was in post meeting emails that have been put together in an attached word document. One take home message from the workshop included the apparent matching of the 1/2 life of the Elcombe et al. (2013) clinical study of 1.8 years by Harvey Clewell's group with the 1/2 life of 1.48 years by Xu et al. (2020, see the case study writeup, Table 1) when background is subtract out. This matching of clinical findings and this observational study is important, and maybe even sentinel.

Additional work may involve the estimation of the volume of distribution (Vd) of PFOA in humans from the Elcombe et al. (2013) clinical study when compared with experimental animal species. Additional lines of research might be the potential conduct of a PFOA human clearance study using existing body burden, and the ascertainment of PFOA health effects in human observational/occupational studies, if any, below the level thought to increase ppar alpha.

A workshop report is in preparation and will be posted, after appropriate review by the workshop participants, by about the end of April.

Cheers!

Michael Dourson

—Alliance for Risk Assessment (ARA), building a risk assessment community

On Feb 3, 2021, at 9:25 AM, Michael Dourson <dourson@tera.org> wrote:

Dear Colleagues

Attached is the preliminary research case study that our group will be presenting at the upcoming ARA workshop (agenda also attached). Your thoughts ahead of time, or at the workshop, would be welcome. Registration is free at: <https://tera.org/Alliance%20for%20Risk/WS12WR.html>.

Cheers!

Michael

---Those who have the privilege to know, have the duty to act. Albert Einstein

COMMITTEES ASSOCIATED WITH THE ALLIANCE FOR RISK ASSESSMENT

The current Steering Committee of the Alliance for Risk Assessment, which continues to endorse this workshop series

- Annette Dietz, Portland State University
- Michael Dourson, Toxicology Excellence for Risk Assessment
- Michael Honeycutt, Texas Commission on Environmental Quality
- Matthew McAtee, US Army
- Moiz Mumtaz, Agency for Toxic Substance & Disease Registry
- Ralph Perona, Neptune & Company, Inc. [representing tribal interests]

Risk current Assessment Advisory Committee of this workshop series

- James Bus, Exponent
- Michael Dourson, TERA
- Neeraja Erraguntia, ACC
- Suzanne Fitzpatrick, US FDA
- Mark Johnson, USARMY
- Sabine Lange, TCEQ
- Pam Williams, Erisksciences

The Science Panel of Workshop XI

- James Bus, Exponent
- Chris Chaisson, The Lifeline Group
- Michael Dourson, TERA
- Annie Jarabek, US EPA
- Bette Meek, University of Ottawa
- Greg Paoli, Risk Sciences International

Ad hoc for Workshop XII

- Alan Boobis
- Harvey Clewell
- Laurie Haws
- John Lipscomb
- Wally Hayes